Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710253 · ClinicalTrials.gov registry record · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
A Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 5
- Study locations
NCT02710253 is a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 230 participants, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT02710253, a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Metastatic Malignant Solid Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to control the cancer after the disease has gotten worse after receiving immunotherapy in patients with cancer that has spread to the other places in the body.
Conditions Studied
Interventions
- RADIATION External Beam Radiation Therapy
- RADIATION Stereotactic Body Radiation Therapy
- OTHER Laboratory Biomarker Analysis
Study Locations (5)
Texas
- MD Anderson in The Woodlands - Conroe
- M D Anderson Cancer Center - Houston
- MD Anderson West Houston - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710253
The ClinicalTrials.gov registry entry for NCT02710253 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 951-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (76% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which External Beam Radiation Therapy is the first listed.
NCT02710253 reports 5 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02710253 about?
NCT02710253 is a clinical study titled "Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy". This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to...
What is the current status of trial NCT02710253?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2016-05-25. Estimated completion is 2026-05-30.
What conditions does trial NCT02710253 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm.
What interventions are being tested in trial NCT02710253?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Stereotactic Body Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02710253?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710253 being conducted?
This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
ACTIVE NOT RECRUITING · Phase 2
-
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
ACTIVE NOT RECRUITING · Phase 2
-
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
Metastatic Malignant Solid Neoplasm
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.